Cardiovascular Outcomes Trials For Opioid Agonists To Get FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix and Progenics’ appeal of FDA’s “complete response” letter for Relistor argues that potential safety issues for the opioid-induced constipation claim could be handled in a post-marketing study.